Patent ID: 6841345

Claim:
An in vitro method of reducing human immunodeficiency virus (HIV-1) replication in monocytes comprising introducing to the monocytes a composition comprising a variant lipopolysaccharide (LPS) component in an amount effective to reduce HIV replication therein, wherein the variant LPS is an isolated and purified LPS component obtained from a double mutant E. coli which is designated E coli htrB1::Tn10 msbB::Ωcam strain having ATCC Accession No. PTA-2794, wherein the LPS component has the following properties: (a) exhibits reduced pyrogenicity relative to a wild-type E. coli lipopolysaccharide; (b) stimulates β chemokine secretion from the mononuclear cells; (c) reduces secretion of TNF-α proinflammatory relative to a wild-type E. coli lipopolysaccharide; and (d) reduces replication of HIV in the monocytes.